Abstract
Background Immunodaat™, a proprietary botanical extract, contains standardized extract of Elderberry (Sambucus Nigra L.). Elderberry is used as an immunity enhancer for prevention and management of various respiratory diseases and as an anti-oxidant.
Objectives The present study evaluated the effect of Immunodaat™, in Post Covid-19 recovery.
Methods An open labeled, comparative, randomized, multi-centric, prospective clinical study was conducted on 74 subjects who had post COVID-19 symptoms recovery from mild-moderate COVID-19 within the last 15 days. Subjects were divided equally, with 37 subjects in trial and control groups each, where subjects in trial group were given Immunodaat™ capsules in a dose of 250 mg Capsules twice daily along with the standard care for COVID-19 for consecutive 30 days while subjects in control group were given only the standard care for Post Covid. Subjects were evaluated for post clinical recovery signs and symptoms (like cough, fatigue, Myalgia, Joint pain, confusion, altered mood, anxiety, insomnia etc.) and lab parameters. Subjects were evaluated for quality of life using WHO QOL BREF.
Results Continuous 30 days administration of Immunodaat™ showed a significant difference in reducing physical as well as mental symptoms when compared to the control group. Also, a significant improvement in quality of life was observed on WHO QOL BREF scale with the use of Immunodaat compared to the control group. Overall quality of life, energy levels and stamina levels improved with the use of Immunodaat™.
Subjects showed excellent tolerability and did not have any adverse effect with the use of Immunodaat™.
Conclusion The study concludes that use of Immunodaat™ over 30 days aided to normalize the physical and mental symptoms that occurred due to Post COVID and long COVID. Immunodaat™ can be considered as a safe and effective natural ingredient in the management of Post COVID-19 or long COVID condition.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2021/06/034433 [Registered on: 29/06/2021]
Funding Statement
Lodaat Pharma, USA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted at two sites in India. The institutional ethics committees of KVTR Ayurved Institute and Hospital, Boradi, Maharashtra, India and Parul Ayurveda Institute and Hospital, Vadodra, Gujrat, India gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The names and affiliations of all the authors have been added after title in the main manuscript file.
Data Availability
All data produced in the present work are contained in the manuscript.
